Zevra Therapeutics

ZVRA · NASDAQ

$10.47+$0.31 (+3.05%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $10.16

Latest news

Press releaseOct 20, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
NewsOct 8, 8:07 AM ETAvi Kapoor
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
NewsSep 2, 8:03 AM ETAvi Kapoor
MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseAug 6, 11:02 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
NewsAug 5, 5:56 PM ET
UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate
NewsAug 5, 4:23 PM ET
Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate
Press releaseAug 4, 5:40 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Press releaseAug 3, 10:38 AM ETGlobe Newswire
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Press releaseAug 3, 10:07 AM ETPRNewswire
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Press releaseJul 30, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Press releaseJul 29, 10:07 AM ETBusiness Wire
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
Press releaseJul 28, 10:09 AM ETPRNewswire
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
Press releaseJul 27, 8:40 PM ETBusiness Wire
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
Press releaseJul 27, 5:19 PM ETPRNewswire
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)
NewsJul 24, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsJul 24, 12:47 PM ETVandana Singh
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C
NewsJul 24, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsJul 24, 7:33 AM ET
Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C
Press releaseJul 24, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
Press releaseJul 22, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
Press releaseJun 11, 8:30 AM ETGlobe Newswire
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Press releaseJun 8, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
NewsMay 6, 5:23 PM ET
CORRECTION: Zevra Therapeutics Q1 Adj. EPS $0.18 Beats $0.08 Estimate, Sales $36.220M Beat $31.960M Estimate
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseApr 22, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
NewsMar 10, 2:45 PM ETNabaparna Bhattacharya
Why Is Zevra Therapeutics Stock Trading Higher Today?
NewsMar 10, 1:19 PM ETAvi Kapoor
Dow Jumps Over 300 Points; Kohl's Posts Upbeat Earnings
Press releaseMar 10, 8:30 AM ETBusiness Wire
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
NewsMar 10, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 9, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseMar 9, 4:05 PM ETGlobe Newswire
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseMar 2, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Press releaseFeb 18, 1:51 PM ETBusiness Wire
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
NewsNov 3, 9:14 AM ETErica Kollmann
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Press releaseOct 27, 7:30 AM ETGlobe Newswire
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
NewsSep 3, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsAug 13, 3:19 PM ETAvi Kapoor
Crude Oil Down 1%; Performance Food Group Earnings Top Views
NewsAug 13, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsAug 13, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsAug 12, 5:07 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsAug 11, 11:03 AM ET
A Look at Zevra Therapeutics's Upcoming Earnings Report
NewsJul 2, 8:35 AM ETAvi Kapoor
This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate

Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

12 Health Care Stocks Moving In Friday's Intraday Session

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

12 Health Care Stocks Moving In Friday's Pre-Market Session

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

CORRECTION: Zevra Therapeutics Q1 Adj. EPS $0.18 Beats $0.08 Estimate, Sales $36.220M Beat $31.960M Estimate

Earnings Scheduled For May 6, 2026

Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

Why Is Zevra Therapeutics Stock Trading Higher Today?

Dow Jumps Over 300 Points; Kohl's Posts Upbeat Earnings

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

12 Health Care Stocks Moving In Wednesday's After-Market Session

Crude Oil Down 1%; Performance Food Group Earnings Top Views

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

A Look at Zevra Therapeutics's Upcoming Earnings Report

This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday